[1] 中华医学会感染病学分会肝衰竭与人工肝学组;中华医学会肝病学分会重型肝病与人工肝学组.肝衰竭诊治指南(2018年版).实用肝脏病杂志,2019,22(2):164-171. [2] Ducci H, Katz R. Cortisone, ACTH and antibiotics in fulminant hepatitis.Gastroenterology,1968,54(4):757-759. [3] Gregory PB,Knauer CM,Kempson RL,et al.Steroid therapy in severe viral hepatitis. A double-blind, randomized trial ofmethyl-prednisolone versus placebo. N Engl J Med,1976, 294(13):681-687. [4] Randomised trial of steroid therapy in acute liver failure. Report from the European Association for the Study of the Liver (EASL).Gut,1979,20(7):620-623. [5] Ware AJ,Jones RE,Shorey JW,et al.A controlled trial of steroid therapy in massive hepatic necrosis.Am J Gastroenterol,1974, 62(2):130-133. [6] Rakela J,Mosley JW,Edwards VM,et al.A double-blinded, randomized trial of hydrocortisone in acute hepatic failure. The Acute Hepatic Failure Study Group.Dig Dis Sci,1991,36(9) :1223-1228. [7] Fujiwara K,Yasui S,Yonemitsu Y,et al.Effcacy of combination therapy of antiviral and immunosuppressive drugs for the treatment of severe acute exacerbation of chronic hepatitis B. J Gastroenterol,2008,43:711-719. [8] Wu Z,Han M,Chen T,et al.Acute liver failure:Mechanisms of immune-mediated liver injury.Liver Int,2010,30(6):782-794. [9] Lu YS,Pu LY,Li XC,et al.Methylprednisolone inhibits activated CD4+ T cell survival promoted by toll-like receptor ligands.Hepatobiliary Pancreat Dis Int,2010, 9(4):376-383. [10] Spies CM,Strehl C,van der Goes MC,et al.Glucocorticoids.Best Pract Res Clin Rheumatol,2011,25(6):891-900. [11] Etogo-Asse FE,Atogo-Asse FE,Vincent RP,et al.High density lipoprotein in patients with liver failure; relation to sepsis, adrenal function and outcome of illness.Liver Int,2012,32(1) :128-136. [12] 陈从新, 郭顺明, 刘波, 等.糖皮质激素阻断慢性乙型肝炎肝衰竭发生的临床对照观察.中华肝脏病杂志,2003,11( 1 ): 37-40. [13] Garg H,Sarin SK,Kumar M,et al.Tenofovir improves the outcome in patients with spontaneous reactivation of hepatitis B presenting as acute-onchronic liver failure. Hepatology,2011,53:774-780. [14] Cui YL,Yan F,Wang YB,et al.Nucleoside analogue can improve the long-term prognosis of patients with hepatitis B virus infection-associated acute on chronic liver failure.Dig Dis Sci,2010,55(8) :2373-2380. [15] Fujiwara K,Yokosuka O,Kojima H,et al.Importance of adequate immunosuppressive therapy for the recovery of patients with“life-threatening”severe exacerbation of chronic hepatitis B.World J Gastroenterol,2005,28,11(8):1109-1114. [16] Chisari FV,Ferrari C.Hepatitis B virus immunopathogenesis.Annu Rev Immunol,1995,13:29-60. [17] Sjogren MH,Hoofnagle JH,Waggoner JG.Effect of corticosteroid therapy on levels of antibody to hepatitis B core antigen in patients with chronic type B hepatitis. Hepatology,1987,7:582-585. [18] Fujiwara K,Yasui S,Yonemitsu Y, et al.Efficacy of high-dose corticosteroid in the early stage of viral acute liver failure.Hepatol Res,2014,44(5):491-501. [19] Tur-Kaspa R,Burk RD,Shaul Y,et al.Hepatitis B virus DNA contains a glucocorticoid-responsive element.Proc Natl Acad Sci U S A.1986,83(6):1627-1631. [20] He B,Zhang Y,Lü MH,et al.Glucocorticoids can increase the survival rate of patients with severe viral hepatitis B: a meta-analysis.Eur J Gastroenterol Hepatol,2013,25(8):926-934. [21] 叶一农,高志良.乙型肝炎肝衰竭发生机制中的三重打击.传染病信息,2009,22(5):276-278. [22] Sebode M,Hartl J,Vergani D.Autoimmune hepatitis: From current knowledge and clinical practice to future research agenda.Liver Int,2018,38(1):15-22. [23] Liberal R,Grant CR,Longhi MS,et al.Regulatory T cells: Mechanisms of suppression and impairment in autoimmune liver disease.IUBMB Life,2015,67(2):88-97. [24] Oh HY,Namkoong S,Lee SJ,et al.Dexamethasone protects primary cultured hepatocytes from death receptor-mediated apoptosis by upregulation of cFLIP.Cell Death Differ,2006,13(3):512-523. [25] Taubert R,Hardtke-Wolenski M,Noyan, F,et al.Intrahepatic regulatory T cells in autoimmune hepatitis are associated with treatment response and depleted with current therapies.J Hepatol,2014,61(5):1106-1114. [26] European Association for the Study of the Liver.EASL Clinical Practice Guidelines: Autoimmune hepatitis.J Hepatol,2015,63(4):971-1004. [27] Ichai P,Duclos-Vallée JC,Guettier C,et al.Usefulness of corticosteroids for the treatment of severe and fulminant forms of autoimmune hepatitis.Liver Transpl,2007,13(7):996-1003. [28] Yeoman AD,Westbrook RH,Zen Y,et al.Prognosis of acute severe autoimmune hepatitis (AS-AIH): the role of corticosteroids inmodifying outcome.J Hepatol,2014,61(4):876-882. [29] Montano-Loza AJ, Carpenter HA, Czaja AJ.Features associated with treatment failure in type 1 autoimmune hepatitis and predictive value of the model of end-stage liver disease.Hepatology,2007,46(4):1138-1145. [30] Anastasiou OE,Dogan-Cavus B,Kucukoglu O,et al.Corticosteroid therapy improves the outcome of autoimmune hepatitis-induced acute liver failure.Digestion,2018,98(2):104-111. [31] European Association for the Study of Liver.EASL clinical practicalguidelines:management of alcoholic liver disease.J Hepatol,2012,57(2):399-420. [32] Mathurin P,O'Grady J,Carithers RL,et al.Corticosteroids improve short-term survival in patients with severe alcoholic hepatitis: meta-analysis of individual patient data.Gut,2011,60(2):255-260. [33] Thursz MR,Richardson P,Allison M,et al.Prednisolone or pentoxifylline for alcoholic hepatitis.N Engl J Med,2015,23,372(17) :1619-1628. [34] Louvet A,Naveau S,Abdelnour M,et al.The Lille model: a new tool for therapeutic strategy inpatients with severe alcoholic hepatitis treated with steroids.Hepatology,2007,45(6):1348-1354 [35] Karkhanis J,Verna EC,Chang, MS,et al. Steroid use in acute liver failure.Hepatology,2014,59(2):612-621. |